The latest new contracts, like Nordicus Partners Corporation’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.
Nordicus Partners Corporation has announced that it entered into an agreement with Bio-Convert ApS to acquire 100% of its shares outstanding for 12 million of the Company's restricted common shares in an all-stock transaction to the selling shareholders. Bio-Convert ApS is a Denmark-based clinical-stage biopharmaceutical company focused on revolutionizing the treatment of oral leukoplakia, and Nordicus Partners Corporation aims to support Bio-Convert's mission through this acquisition.
Company Information
Company
Nordicus Partners Corporation
Location
Denmark
About
Nordicus Partners Corporation is a Denmark-based financial consulting company, specializing in providing Nordic and U.S. life sciences companies with the best possible conditions to establish themselves on the U.S. market. Nordicus’ 95% owned subsidiary, Orocidin A/S, is a clinical-stage biopharmaceutical company which is advancing the next generation of periodontitis therapies. Nordicus’ core competencies lie in assisting Danish as well as other Nordic and international companies in different areas of corporate finance activities.
Predictive Intelligence
Strategic
ML-powered predictions for Nordicus Partners Corporation's next move
DenmarkBiotechnology